161 related articles for article (PubMed ID: 31108222)
1. Urinary piperacillin/tazobactam pharmacokinetics in vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriaceae.
Gould M; Ginn AN; Marriott D; Norris R; Sandaradura I
Int J Antimicrob Agents; 2019 Aug; 54(2):240-244. PubMed ID: 31108222
[TBL] [Abstract][Full Text] [Related]
2. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing
Abodakpi H; Chang KT; Gao S; Sánchez-Díaz AM; Cantón R; Tam VH
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530606
[TBL] [Abstract][Full Text] [Related]
3. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
Guet-Revillet H; Tomini E; Emirian A; Join-Lambert O; Lécuyer H; Zahar JR; Jullien V
Int J Antimicrob Agents; 2017 Jan; 49(1):62-66. PubMed ID: 27876276
[TBL] [Abstract][Full Text] [Related]
4. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Bulik CC; Tessier PR; Keel RA; Sutherland CA; Nicolau DP
Antimicrob Agents Chemother; 2012 Jan; 56(1):544-9. PubMed ID: 22064538
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.
Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
Int J Antimicrob Agents; 2017 Feb; 49(2):189-197. PubMed ID: 27988068
[TBL] [Abstract][Full Text] [Related]
6. Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance.
Abdelraouf K; Chavda KD; Satlin MJ; Jenkins SG; Kreiswirth BN; Nicolau DP
Int J Antimicrob Agents; 2020 Mar; 55(3):105885. PubMed ID: 31923568
[TBL] [Abstract][Full Text] [Related]
7. SHV Hyperproduction as a Mechanism for Piperacillin-Tazobactam Resistance in Extended-Spectrum Cephalosporin-Susceptible
Han MS; Park KS; Jeon JH; Lee JK; Lee JH; Choi EH; Lee SH
Microb Drug Resist; 2020 Apr; 26(4):334-340. PubMed ID: 31651221
[TBL] [Abstract][Full Text] [Related]
8. A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae.
Abodakpi H; Chang KT; Zhou J; Byerly C; Tam VH
Clin Microbiol Infect; 2019 Sep; 25(9):1154.e9-1154.e14. PubMed ID: 30664934
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an
VanScoy BD; Tenero D; Turner S; Livermore DM; McCauley J; Conde H; Bhavnani SM; Rubino CM; Ambrose PG
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947475
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
Cojutti PG; Morandin E; Baraldo M; Pea F
Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
[TBL] [Abstract][Full Text] [Related]
12. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
13. Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli.
Schechter LM; Creely DP; Garner CD; Shortridge D; Nguyen H; Chen L; Hanson BM; Sodergren E; Weinstock GM; Dunne WM; van Belkum A; Leopold SR
mBio; 2018 Apr; 9(2):. PubMed ID: 29691340
[TBL] [Abstract][Full Text] [Related]
14. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Raveh D; Yinnon AM; Broide E; Rudensky B
Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
[TBL] [Abstract][Full Text] [Related]
16. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
[TBL] [Abstract][Full Text] [Related]
17. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
Kanji S; Roberts JA; Xie J; Alobaid A; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
Ann Pharmacother; 2018 Oct; 52(10):965-973. PubMed ID: 29730948
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.
Sutherland CA; Nicolau DP
Clin Ther; 2015 Jul; 37(7):1564-71. PubMed ID: 26088525
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.
Hertz FB; Andreasen MR; Almind SR; Nielsen KL; Hansen KH; Jelsbak L; Frimodt-Møller N; Schønning K
Int J Antimicrob Agents; 2022 Apr; 59(4):106543. PubMed ID: 35134504
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
Burgess DS; Waldrep T
Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
